Crossmark

Assessment of the physiological effects and safety of transpulmonary chemoembolization with doxorubicin on pulmonary tissue using a human-isolated lung perfusion model

Crossref DOI link: https://doi.org/10.1186/s41747-024-00532-3

Published Online: 2024-12-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Slama, Alexis

Steinberg, Hannah

Collaud, Stéphane

Okumus, Özlem

Hilger, Ralph-Axel

Bauer, Sebastian

Schildhaus, Hans-Ulrich

Aigner, Clemens

Schaarschmidt, Benedikt M. https://orcid.org/0000-0001-6331-7679
Funding

Funding for this research was provided by:

PharmaCept AG
License Information

Text and Data Mining valid from 2024-12-05

Version of Record valid from 2024-12-05
More Information

Article History

Received: 22 July 2024

Accepted: 26 October 2024

First Online: 5 December 2024

Declarations

:

: The study was approved by the institutional review board of the University of Duisburg Essen. Informed consent was obtained from all patients prior to surgery.

: Not applicable.

: The authors declare no competing interests regarding this research project.

Document is current

Any future updates will be listed below